AKR1C1
AKR1C1 (aldo-keto reductase family 1 member C1) is a cytosolic NADPH-dependent reductase that converts ketosteroids to hydroxysteroids, chiefly 20alpha-hydroxysteroids. It is also known as DDH, DDH1, DD1, MBAB and HAKRC. Browse Assay Genie's current range of AKR1C1 research reagents below, or read on for the biology behind the target.
AKR1C1 is a cytosolic aldo-keto reductase that catalyses the NADPH-dependent reduction of ketosteroids to hydroxysteroids. It shows broad substrate specificity with distinct positional and stereochemical preferences, primarily generating 20alpha-hydroxysteroids but also 3alpha/beta- and 17beta-hydroxysteroids. It reduces progesterone to the less potent progestogen (20S)-hydroxypregn-4-en-3-one, which is likely to regulate ligand availability for progesterone receptors.
The enzyme is also involved in neurosteroid metabolism. It reduces 5alpha-dihydrodeoxycorticosterone to the neuroactive steroid 3alpha,5alpha-tetrahydrodeoxycorticosterone, which alters neural excitability through allosteric activation of GABAA receptors. It also inactivates 3alpha,5alpha-THP to a less potent neurosteroid. In androgen catabolism, AKR1C1 may act mainly as a phase I enzyme, introducing a hydroxyl group before conjugation, although it can take part in an alternative phase II pathway by directly reducing sulfate- or glucuronide-conjugated androgens. In vitro it catalyses bidirectional conversion using NADPH/NADP+ or NADH/NAD+, but in vivo reductase activity prevails because NADPH inhibits NAD+-dependent oxidase activity.
The AKR1C1 gene encodes a member of the aldo/keto reductase superfamily, which includes more than 40 enzymes and proteins that convert aldehydes and ketones to alcohols using NADH and/or NADPH. Members display overlapping but distinct substrate specificity. AKR1C1 shares high sequence identity with three other genes and is clustered with them on chromosome 10p15-p14. Earlier names, including dihydrodiol dehydrogenase 1 and 20-alpha (3-alpha)-hydroxysteroid dehydrogenase, reflect its enzymatic activities.
AKR1C1 reduces ketosteroids to hydroxysteroids, making it a useful enzyme for studying how steroid potency and availability are controlled.
By converting progesterone to a less potent progestogen, AKR1C1 is likely to regulate ligand availability for progesterone receptors.
AKR1C1 modulates neuroactive steroids that act on GABAA receptors and alter neural excitability.
AKR1C1 may act as a phase I enzyme and can also reduce conjugated androgens in an alternative phase II pathway.
AKR1C1 is a cytosolic enzyme that uses NADPH to reduce ketosteroids to hydroxysteroids, mainly 20alpha-hydroxysteroids. It inactivates progesterone and certain neurosteroids and takes part in androgen catabolism. In vivo its reductase activity prevails over oxidase activity.
AKR1C1 is also called DDH, DDH1, DD1, MBAB and HAKRC. Its earlier HGNC name was aldo-keto reductase family 1, member C1, with the descriptors dihydrodiol dehydrogenase 1 and 20-alpha (3-alpha)-hydroxysteroid dehydrogenase.
AKR1C1 belongs to the aldo/keto reductase family. Its gene shares high sequence identity with three other genes and clusters with them on chromosome 10p15-p14. These enzymes have overlapping but distinct substrate specificity. Check the datasheet of any product for its validated reactivity.
Other aldo-keto reductases, including the AKR1C cluster members, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q04828; product specifications from Assay Genie datasheets.